Epitheloid hemangioendothelioma (EHE) is a rare vascular neoplasm of intermediate malignant potential. EHE commonly involves lungs, liver soft tissue, and bone. EHE is extremely rare in tongue and up to our best knowledge only 
Introduction
Epitheloid hemangioendothelioma (EHE), a rare subtype of hemangioendothelioma was first reported in 1982 by Weiss and Enzinger. [1] EHE is a vascular tumor considered and intermediate neoplasm between hemangioma (benign) and angiosarcoma (malignant).
[2] Occurrence of EHE is exceedingly rare in oral cavity; an exhaustive literature review could reveal only 31 cases. Tongue is considered a rare site in oral cavity with only nine reported cases so far. [3] EHE tends to show local recurrence. [4] EHE is characterized microscopically by neoplastic proliferation of epitheloid and histiocytoid endothelial cells. [2] Microscopical differential diagnoses of EHE include carcinoma, hemangiopericytoma, angiosarcoma angiofibroma, and angioleiomyoma. [4] [5] [6] An immunohistochemical work up using different panels of tumor markers is required to arrive at a final diagnosis. [2] The clinical course of EHE is usually benign with a painless mass. Intra-orally, it imitates different benign tumors including pyogenic granuloma, lipoma, fibroma, peripheral giant cell granuloma, and so on. [7] We report a case of EHE presented as a painless swelling on the base of the tongue which was provisionally diagnosed as lipoma. Histopathological and immunohistochemical features confirmed the diagnosis of EHE. [2] Intra-orally, gingiva is the common site followed [4] revealed that most of the cases of oral EHE clinically presented as reddish, erosive, or purplish soft tissue growth. However, the present case was contrary to their finding and the color of the lesion in the present case was found to be similar to the adjacent mucosa, which clinically imitated a lipoma. Most of the cases of oral EHE initiated as a painless mass although ulcerated lesions have been reported too. [12] The etiology of EHE is not very clear; recently Tanas RM et al. [13] proposed that reciprocal translocation of chromosome 1 and 3 is responsible for the fusion of two different genes namely WWTR1 and CAMTA1. This fusion was found to be positive in 90% cases of hemangioendothelioma. [13] [14] Microscopically, oral EHE is and CAMTA1 has been developed that offers the pathologists to identify the fusion of the two genes, which is specific for EHE. Treatment of choice for oral EHE is a wide surgical excision with a proper follow up considering the recurrence and malignant potential of the lesion. [13] The Chimeric WWTR1/ CAMTA1 transcription factor offers a therapeutic target for EHE and offers some insight on the mechanism of both genes. The differentiation between EHE and carcinoma can be achieved by vascular markers i.e. CD 34, CD 31, and Factor VIII.
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